Status:
COMPLETED
Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's Disease
Lead Sponsor:
United Biomedical
Collaborating Sponsors:
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50-80 years
Phase:
PHASE1
Brief Summary
The purpose of this Phase I study is to determine whether the vaccine (UB 311), targeting the amyloid beta peptide (N-terminal amino acids, 1-14), is safe and immunogenic in patients diagnosed with mi...
Eligibility Criteria
Inclusion
- Diagnosis of mild to moderate Alzheimer's Disease
- Mini-Mental State Examination (MMSE) 15-25
- Other inclusion criteria apply
Exclusion
- Major psychiatric disorder
- Severe systemic disease
- Serious adverse reactions to any vaccine
- Other exclusion criteria apply
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00965588
Start Date
February 1 2009
End Date
April 1 2011
Last Update
August 23 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital (NTUH)
Taipei, Taiwan, 10002
2
Taipei Veterans General Hospital
Taipei, Taiwan, 11217